For the second time in three years, Amgen is turning to a smaller biotech to continue clinical development of an experimental celiac disease drug that was developed in its labs.
Under a deal announced Monday, Provention Bio (NASDAQ: PRVB) will... Read more »
Broadcom is selling application security testing business Veracode for $950 million to private equity firm Thoma Bravo. Broadcom gained Veracode as a part of its blockbuster acquisition of CA Technologies.
Broadcom (NASDAQ: AVGO) announced in June it would acquire CA... Read more »
The second-most advanced investigational drug in MEI Pharma’s four-asset portfolio is drawing attention from overseas as a potential treatment for several leukemias and lymphomas.
Japanese life sciences company Kyowa Hakko Kirin has agreed to pay the San Diego company $10 million... Read more »
San Antonio — A Texas billionaire is funding a new competition that will give $4 million to seven individuals who present promising ideas about the cause of Alzheimer’s disease and say they’ll work to prove it.
Called the Oskar Fischer Project,... Read more »
The gene-editing technology CRISPR-Cas9 is opening up new research avenues all the time, such as giving drug developers a cheaper, faster way to knock out genes in tumor cells.
Studies of CRISPR-Cas9 to treat human disease are about to start,... Read more »
In some ways, the biggest software acquisition of all time could be a yawner.
IBM’s planned $34 billion deal to acquire open-source software maker Red Hat is a hefty price to pay to give its cloud computing business a shot in... Read more »
Autonomous vehicle developers rely heavily on navigational technology that maps the complex terrain of roads, curbs, signs, and people that their cars have to thread through.
Google, as it develops its smart home systems, is turning to a company that already... Read more »
GlaxoSmithKline’s former gene therapy portfolio is at the center of a $200 million IPO, among the larger biopharma offerings on Wall Street over the last several years.
Orchard Therapeutics, a London, Boston, and San Francisco-based biotech, sold 14,285,715 shares in its... Read more »
Facebook (NASDAQ: FB) shares gained nearly 3 percent Tuesday, and ticked up further in after-hours trading following the release of a third quarter earnings report that showed some strengths as well as shortfalls. Investors have been concerned about the social... Read more »